focus -WSS

focus

author：leisure time 2025-10-01 21:48:02 - browse：643

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

hotspot

WSS

A former Republican legislative candidate has been charged for his role in the US Capitol riot

Trump Organization, Michael Cohen agree to settle million

Mega Millions jackpot grows to $720 million ahead of Friday's drawing

The drug industry sees a key ally in the Senate prevail

Influencer to be charged after chaos erupts in New York City's Union Square

'The View' co

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Affirmative action in medical school literally saved lives

Trump Organization, Michael Cohen agree to settle million

In age of alternative facts, a scholarly course on calling out crap

The biotech scorecard for the 2nd quarter: 12 industry events to watch

State Dept. review finds Biden bears some blame for Afghanistan failures

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Novavax promises a turnaround & Lilly roils the obesity market

Pfizer's RSV vaccine recommended for approval in Europe

Affirmative action in medical school literally saved lives

What Mike Pence has said that could be used in a Donald Trump trial

knowledge

Stem cell clinics for heart failure: buyer be wary

My superpower is killing ticks

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

'Ancient DNA,' 23andMe reveal African American ancestries

What the cancer research community can learn from the Covid response

leisure time

focus

hotspot

explore